Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHST BioHarvest Sciences	$8.40 -6.7%	$7.67	$4.66 ▼ $9.90	$137.97M	0.68	15,587 shs	4,378 shs
BTMD biote	$3.36 +1.5%	$3.81	$2.76 ▼ $6.98	$166.12M	1.21	172,969 shs	148,820 shs
CALC CalciMedica	$2.90 +1.0%	$2.50	$1.42 ▼ $5.97	$40.51M	1.33	47,324 shs	8,643 shs
GLSI Greenwich LifeSciences	$11.67 -2.2%	$10.91	$8.06 ▼ $16.50	$159.06M	1.65	57,501 shs	15,585 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHST BioHarvest Sciences	+8.43%	-2.28%	+18.73%	+41.73%	+899,999,900.00%
BTMD biote	+2.48%	+9.60%	-23.38%	-6.23%	-46.00%
CALC CalciMedica	+2.87%	+3.24%	-24.47%	+64.56%	-30.51%
GLSI Greenwich LifeSciences	+0.34%	+4.01%	+3.11%	+22.74%	-18.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BTMD biote	2.9607 of 5 stars	3.3	2.0	0.0	0.0	3.8	1.7	1.3
CALC CalciMedica	3.4791 of 5 stars	3.5	5.0	0.0	0.0	3.0	3.3	0.0
GLSI Greenwich LifeSciences	1.7762 of 5 stars	3.5	0.0	0.0	0.0	3.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHST BioHarvest Sciences	3.00	Buy	$13.67	62.70% Upside
BTMD biote	2.50	Moderate Buy	$6.00	78.57% Upside
CALC CalciMedica	3.00	Buy	$16.00	451.72% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$42.00	259.90% Upside

Current Analyst Ratings Breakdown

Latest CALC, BTMD, GLSI, and BHST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/20/2025	GLSI Greenwich LifeSciences	Noble Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
8/7/2025	BTMD biote	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$8.00 ➝ $4.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHST BioHarvest Sciences	$30.19M	4.57	N/A	N/A	($0.26) per share	-32.31
BTMD biote	$199.07M	0.83	$0.80 per share	4.22	($1.59) per share	-2.11
CALC CalciMedica	N/A	N/A	N/A	N/A	$0.44 per share	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.11 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHST BioHarvest Sciences	-$12.91M	-$0.70	N/A	N/A	N/A	-39.95%	-11,357.84%	-39.94%	N/A
BTMD biote	$3.16M	$0.90	3.73	6.22	N/A	15.73%	-21.00%	18.26%	11/11/2025 (Estimated)
CALC CalciMedica	-$13.70M	-$1.60	N/A	N/A	N/A	N/A	-206.51%	-103.81%	11/12/2025 (Estimated)
GLSI Greenwich LifeSciences	-$15.79M	-$1.36	N/A	N/A	N/A	N/A	-700.90%	-455.64%	11/13/2025 (Estimated)

Latest CALC, BTMD, GLSI, and BHST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.30	-$0.06	-$0.30	N/A	N/A
8/12/2025	Q2 2025	CALC CalciMedica	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/11/2025	Q2 2025	BHST BioHarvest Sciences	-$0.1075	-$0.15	-$0.0425	-$0.24	$8.53 million	$8.52 million
8/6/2025	Q2 2025	BTMD biote	$0.06	$0.10	+$0.04	$0.10	$49.52 million	$48.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
BTMD biote	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHST BioHarvest Sciences	N/A	0.60	0.36
BTMD biote	N/A	0.98	0.74
CALC CalciMedica	1.39	5.45	5.45
GLSI Greenwich LifeSciences	N/A	1.85	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHST BioHarvest Sciences	N/A
BTMD biote	21.68%
CALC CalciMedica	N/A
GLSI Greenwich LifeSciences	4.16%

Insider Ownership

Company	Insider Ownership
BHST BioHarvest Sciences	N/A
BTMD biote	24.00%
CALC CalciMedica	41.55%
GLSI Greenwich LifeSciences	51.67%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHST BioHarvest Sciences	N/A	16.43 million	N/A	N/A
BTMD biote	194	49.44 million	37.57 million	Not Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
GLSI Greenwich LifeSciences	3	13.63 million	6.59 million	Not Optionable

CALC, BTMD, GLSI, and BHST Headlines

Recent News About These Companies

What is Noble Financial's Forecast for GLSI Q3 Earnings?

August 24 at 7:32 AM | marketbeat.com

Q3 Earnings Forecast for GLSI Issued By Noble Financial

August 24 at 2:17 AM | americanbankingnews.com

Noble Financial Begins Coverage on Greenwich LifeSciences (NASDAQ:GLSI)

August 22, 2025 | marketbeat.com

Greenwich LifeSciences (NASDAQ:GLSI) Coverage Initiated at Noble Financial

August 22, 2025 | americanbankingnews.com

Greenwich LifeSciences initiated with an Outperform at Noble Capital

August 20, 2025 | msn.com

Greenwich LifeSciences, Inc. Gains Coverage from Noble Capital Markets Amid Phase III Trial of GLSI-100 for Breast Cancer

August 20, 2025 | quiverquant.comQ

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

August 20, 2025 | globenewswire.com

Greenwich LifeSciences to build out internal clinical trial operations team

August 20, 2025 | msn.com

Greenwich LifeSciences, Inc. Expands Internal Clinical Trial Management Team for FLAMINGO-01 Phase III Study

August 19, 2025 | quiverquant.comQ

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

August 19, 2025 | globenewswire.com

Greenwich LifeSciences (NASDAQ:GLSI) Announces Quarterly Earnings Results

August 18, 2025 | marketbeat.com

Owning 53% in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) means that insiders are heavily invested in the company's future

August 16, 2025 | finance.yahoo.com

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

August 13, 2025 | globenewswire.com

Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 2.5% - Still a Buy?

August 12, 2025 | marketbeat.com

Greenwich LifeSciences, Inc. Provides Update on CEO Interviews and Corporate Events Related to GLSI-100 Development

August 11, 2025 | quiverquant.comQ

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

August 11, 2025 | globenewswire.com

Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

June 27, 2025 | azcentral.comA

Greenwich LifeSciences: What The Recent Data Do For The Investment Thesis

May 9, 2025 | seekingalpha.com

Snehal Patel Buys 3,600 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

April 30, 2025 | insidertrades.com

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 5,400 Shares

April 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CALC, BTMD, GLSI, and BHST Company Descriptions

BioHarvest Sciences NASDAQ:BHST

$8.40 -0.60 (-6.67%)

As of 02:32 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

biote NASDAQ:BTMD

$3.36 +0.05 (+1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$3.36 +0.01 (+0.15%)

As of 04:10 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

CalciMedica NASDAQ:CALC

$2.87 0.00 (-0.14%)

As of 04:00 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Greenwich LifeSciences NASDAQ:GLSI

$11.67 -0.26 (-2.18%)

Closing price 04:00 PM Eastern

Extended Trading

$11.67 0.00 (0.00%)

As of 04:45 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time